Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.36 |
| ▸ | HTR2A | P28223 | 10/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 2/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30550680 | 0.91 | HTR2C (0.32) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25322487 | 0.91 | HTR2C (0.32) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25898525 | 0.83 | HTR2C (0.40) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25321710 | 0.80 | TNF (0.39) | GRM2HDAC3HDAC1HDAC6TNF | |
| SCHEMBL25323865 | 0.74 | GRM2 (0.34) | GRM2 | |
| SCHEMBL25897715 | 0.74 | HTR2A (0.49) | HTR2CHTR2AGRM2HDAC3HDAC1 | |
| SCHEMBL25899446 | 0.73 | BRD4 (0.38) | — | |
| SCHEMBL25322354 | 0.71 | TNF (0.32) | TNF | |
| SCHEMBL30550743 | 0.71 | TNF (0.32) | TNF | |
| SCHEMBL26782295 | 0.71 | TNF (0.32) | TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | HTR2C 1861/4885HTR2A 2837/4885CYP1A2 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.